Fox Chase Cancer Center | Strategic Alliance Partners

March 18, 2024

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

March 18, 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

March 12, 2024

Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.

March 11, 2024

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

March 11, 2024

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

March 11, 2024

It is often said that one person can make a difference, but it is also evident that when we band together, we can achieve greatness.

March 04, 2024

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

March 04, 2024

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

February 26, 2024

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

February 26, 2024

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

February 21, 2024

Efrat Dotan, MD, discusses routine provider assessment vs the utility of geriatric assessment in geriatric patients with gastroesophageal disease.

February 15, 2024

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

February 02, 2024

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.

January 18, 2024

Fox Chase Cancer Center was recognized by the ECOG-ACRIN Cancer Research Group for outstanding achievement in accrual, scientific contribution, and more.

January 07, 2024

Zoe Landau, MPH, Project Manager in the lab of Linda Fleisher, PhD, MPH, was recently recognized with the Best Professional Poster Award at the 2023 International Cancer Education Conference for her work detailing the mychoice digital health tool.

January 03, 2024

Fox Chase Cancer Center graduate student Billy Truong was awarded the American Society of Hematology Abstract Achievement Award for the third year in a row for his study on targeting substrate interactions of the ERK2 protein that drive myeloproliferative neoplasms.

December 30, 2023

Edna “Eti” Cukierman, PhD, has been appointed to the newly created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research.

November 24, 2023

Elizabeth Plimack, MD, MS, Deputy Director and Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently recognized as a new fellow of the American Society of Clinical Oncology.

November 11, 2023

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

November 11, 2023

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.